In a report released today, Liana Moussatos from Wedbush maintained a Buy rating on Ascendis Pharma (ASND), with a price target of $191. The company’s shares closed last Monday at $104.45.
According to TipRanks.com, Moussatos is ranked 0 out of 5 stars with an average return of -13.2% and a 30.1% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.
Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $173.
See today’s analyst top recommended stocks >>
The company has a one-year high of $133.96 and a one-year low of $53.21. Currently, Ascendis Pharma has an average volume of 274.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market.
